Tasquinimod
(CAS: 254964-60-8)
Background Information of Tasquinimod
Tasquinimod(ABR-215050) is a quinoline-3-carboxamide linomide analogue with antiangiogenic and potential antineoplastic activities.
Solubility of Tasquinimod
Storage Condition of Tasquinimod
Quality Control and Spectral Data
Mechanism and Indications
Chemical Information
| M.Wt |
Formula |
CAS No. |
Synonyms |
| 406.36 |
C20H17F3N2O4 |
254964-60-8 |
ABR-215050;ABR215050;ABR 215050; 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-(4-(trifluoromethyl)phenyl)-1,2-dihydroquinoline-3-carboxamide |
Structure Information of Tasquinimod
| Smiles |
O=C(C1=C(O)C2=C(N(C)C1=O)C=CC=C2OC)N(C)C3=CC=C(C(F)(F)F)C=C3 |
| InChI |
InChI=1S/C20H17F3N2O4/c1-24(12-9-7-11(8-10-12)20(21,22)23)18(27)16-17(26)15-13(25(2)19(16)28)5-4-6-14(15)29-3/h4-10,26H,1-3H3 |
Related Products
Other Form Products of Tasquinimod
| Name |
CAS |
Formula |
Suppliers |
Recommended Products in Same Target
Recommended Products in the Same Indication
Safety Data of Tasquinimod
Chemical and Physical Properties
| Appearance:White to off-white Solid |
Melting point: |
| Boiling point: |
Flash Point: |
| Water Solubility: |
Solubility:In vitro:DMSO,81 mg/mL(199.33 mM);In vitro:Ethanol,11 mg/mLwarmed(27.06 mM);In vitro:Water,Insoluble;In vivo:Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):5% DMSO+30% PEG 300+ddH2OFor best results, |
| Density: |
Merck: |
| BRN: |
Refractive Index: |
| Vapour: |
EINECS: |
| Optical Rotation: |
alpha: |
Reference
[1].Olsson A, Bj?rk A, Vallon-Christersson J et al. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer. 2010 May 17;9:107.
[2].Jennbacken, Karin; Welen, Karin; Olsson, Anders et al. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050). Prostate (Hoboken, NJ, United States) (2012), 72(8), 913-924.
[3].Dalrymple, Susan L.; Becker, Robyn E.; Zhou, Haoming et al. Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts. Prostate (Hoboken, NJ, United States) (2012), 72(6), 638-648.
[4].Isaacs, John T. The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer. Expert Opinion on Investigational Drugs (2010), 19(10), 1235-1243.
[5].Bratt, O.; Haeggman, M.; Ahlgren, G. et al. Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. British Journal of Cancer (2009), 101(8), 1233-1240.
[6].Clinical Trials
